Maxim Jacobs

Edison Investment Research

Image: Maxim Jacobs

Maxim Jacobs is director of healthcare research, North America, for Edison Research. He joined Edison from Guidepoint Global, where he was a director of survey and tracker research, conducting extensive primary research across healthcare markets. He also brings more than 15 years of experience in equities to the healthcare team. Previously he was a senior healthcare analyst and therapeutic sector head at Ridgemark Capital and Broadfin Capital, and a healthcare analyst at Mehta Partners. Maxim is a CFA charter holder and graduated magna cum laude with a BA in Economics from the University of Pennsylvania.

Recent Quotes

"SNSS' SNS-062 is entering a Phase Ib/II dose escalation/expansion trial starting in Q2/17, targeting completion by September 2018."

— Maxim Jacobs, Edison Investment Research (6/15/17)
more >



Due to permission requirements, not all quotes are shown.